Research-literacy siteEducational evidence reviews only — not medical advice, not dosing guidance, not a protocol for human or animal use. Medical disclaimer.

PeptideStacks

Tirzepatide versus Cagrilintide

Tirzepatide vs Cagrilintide — Incretin vs Amylin Approach to Weight Reduction

Tirzepatide (GIP/GLP-1 agonist, on the MHRA list of licensed GLP-1 medicines) compared with cagrilintide (amylin analogue, investigational): trials, risks and what has not been compared.

Save
FeatureTirzepatideCagrilintide
Brand namesMounjaro (named by the MHRA as the UK brand); Mounjaro and Zepbound in the USNone. Studied alone and as part of CagriSema (cagrilintide plus semaglutide)
ManufacturerEli LillyNovo Nordisk
TypeGIP receptor and GLP-1 receptor agonist (Mounjaro label)Lipidated, long-acting amylin analogue (PMID 34288673)
Half-lifeAbout 5 days (Mounjaro label); 5 to 6 days (Zepbound label)6.6 to 8.1 days (159 to 195 hours), measured with semaglutide alongside (phase 1b trial)
Route and scheduleSubcutaneous, once weekly (US labels)In trials: subcutaneous, once weekly
Placebo-controlled trial of the drug alone, with resultsSURMOUNT-1: 2,539 adults, 72 weeks. Weight fell 20.9% on 15 mg and 3.1% on placebo (PMID 35658024)Phase 2: 706 adults, 26 weeks. Weight fell 6.0% to 10.8% on 0.3 to 4.5 mg and 3.0% on placebo (PMID 34798060)
Phase 3 trials with a cagrilintide-alone armSURMOUNT-1 compared tirzepatide doses with placeboREDEFINE 1 and REIMAGINE 2 each randomised a cagrilintide 2.4 mg arm; in REDEFINE 1 weight fell 11.8% against 2.3% on placebo (PMID 41328546)
Combination trialsNot applicable (a single molecule)REDEFINE 1 and 2 (2025) and REIMAGINE 1 to 3 (2026) tested CagriSema; REIMAGINE 1 and 3 ran 40 weeks, the others 68
Regulatory statusThe MHRA lists tirzepatide (Mounjaro) among licensed GLP-1 medicines (page updated 5 February 2026)No label in DailyMed or openFDA on 6 November 2026

How they differ

Tirzepatide is a GIP receptor and GLP-1 receptor agonist, a single molecule with both actions (Mounjaro label). Cagrilintide is a lipidated, long-acting analogue of amylin, a pancreatic hormone that induces satiety (PMID 34288673; PMID 34798060). It is not a GLP-1 agonist.

CagriSema is different again: a once-weekly combination of two separate molecules, cagrilintide and semaglutide, a GLP-1 receptor agonist (PMID 42251860). So the question "tirzepatide or CagriSema" compares one molecule with two, and most of the phase 3 cagrilintide results are for the combination.

What has been studied

Tirzepatide. SURMOUNT-1 (PMID 35658024) randomised 2,539 adults with obesity, or overweight plus a weight-related complication, and without diabetes, to once-weekly tirzepatide 5, 10 or 15 mg or placebo for 72 weeks, including a 20-week dose-escalation period. Weight at week 72 fell 15.0%, 19.5% and 20.9% on 5, 10 and 15 mg, against 3.1% on placebo. The most common adverse events were gastrointestinal, mostly mild to moderate and mainly during dose escalation. Adverse events caused discontinuation in 4.3%, 7.1% and 6.2% on the three doses and 2.6% on placebo.

The US Zepbound label (effective 28 August 2026) gives a starting dosage of 2.5 mg once weekly for 4 weeks, then increases in 2.5 mg steps after at least 4 weeks until the recommended maintenance dosage is reached, and a maximum of 15 mg once weekly: Zepbound label on DailyMed. The Mounjaro label (effective 27 August 2026) gives the same 2.5 mg starting dosage, says to increase in 2.5 mg steps after at least 4 weeks if additional glycaemic control is needed, and gives a maximum of 15 mg once weekly in adults and 10 mg in children aged 10 and over.

Cagrilintide alone. A 26-week phase 2 trial randomised 706 adults without diabetes to cagrilintide 0.3, 0.6, 1.2, 2.4 or 4.5 mg once weekly (100 to 102 per dose), liraglutide 3.0 mg daily (99) or placebo (101). Weight fell 6.0% to 10.8% on cagrilintide against 3.0% on placebo, and 10.8% against 9.0% for 4.5 mg versus liraglutide (PMID 34798060). Gastrointestinal events occurred in 41% to 63% on cagrilintide against 32% on placebo. REDEFINE 1 (PMID 40544433) and REIMAGINE 2 (PMID 42251859) each randomised a cagrilintide 2.4 mg alone arm (302 and 152 participants). In a later paper that summarises REDEFINE 1, the cagrilintide-alone arm lost 11.8% of body weight against 16.1% on semaglutide, 22.7% on CagriSema and 2.3% on placebo (PMID 41328546); that paper does not say which analysis the figures use, and the main paper's primary treatment-policy figures are 20.4% and 3.0%.

Cagrilintide with semaglutide (CagriSema). In REDEFINE 1 (3,417 adults without diabetes, 68 weeks) weight fell 20.4% on CagriSema 2.4 mg of each against 3.0% on placebo (PMID 40544433). In REDEFINE 2 (1,206 adults with type 2 diabetes, 68 weeks) it fell 13.7% against 3.4% (PMID 40544432). REIMAGINE 1 (189 adults) and REIMAGINE 3 (274 adults on basal insulin) ran 40 weeks, and REIMAGINE 2 (2,713 adults) ran 68 weeks (PMID 42251860; PMID 42251859). The REIMAGINE 2 paper has a published erratum (Lancet Diabetes and Endocrinology 2026;14(8):e11); its figures may differ from the corrected paper. A phase 1b trial gave a half-life for cagrilintide of 159 to 195 hours with semaglutide alongside (PMID 33894838). See the cagrilintide monograph for the trial table.

Head to head. A PubMed search on 6 November 2026 for tirzepatide AND (cagrilintide OR CagriSema) AND "Clinical Trial"[Publication Type] returned 0 records. A ClinicalTrials.gov search on the same date (API query.intr=cagrilintide, query.term=tirzepatide) found three registered trials of CagriSema against tirzepatide: NCT06131437 in obesity (809 enrolled, treatment for up to 84 weeks), and NCT06221969 (1,024 enrolled) and NCT06534411 (1,023 enrolled) in type 2 diabetes. All three are listed as completed, with no results posted. The separate evidence bases cannot be compared directly: different populations, durations and designs.

Risks and unknowns

  • Tirzepatide boxed warning. The Zepbound label warns: "In rats, tirzepatide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures." It also says it is unknown whether tirzepatide causes thyroid C-cell tumours, including medullary thyroid carcinoma, in humans, and that it is contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.
  • Zepbound label warnings. The label (set id 487cd7e7, effective 28 August 2026) states a Limitation of Use: "Coadministration with other tirzepatide-containing products or with any glucagon-like peptide-1 (GLP-1) receptor agonist is not recommended." CagriSema contains the GLP-1 receptor agonist semaglutide. Its Warnings and Precautions section has ten items, listed here with the label's numbers: 5.1 thyroid C-cell tumours (boxed warning above); 5.2 severe gastrointestinal adverse reactions (1.7%, 2.5% and 3.1% on 5, 10 and 15 mg against 1% on placebo in two weight-reduction trials; not recommended in severe gastroparesis); 5.3 acute kidney injury due to volume depletion (0.5% against 0.2%); 5.4 acute gallbladder disease (cholelithiasis 1.1% against 1%, cholecystitis 0.7% against 0.2%, cholecystectomy 0.2% against none); 5.5 acute pancreatitis, including fatal and non-fatal haemorrhagic or necrotising pancreatitis (0.2% against 0.2% confirmed by adjudication; discontinue if suspected); 5.6 serious hypersensitivity reactions (0.1% against none; anaphylaxis and angioedema reported after marketing); 5.7 hypoglycaemia (4.2% against 1.3% in a type 2 diabetes trial, and 10.3% with a sulfonylurea against 2.1% without); 5.8 diabetic retinopathy complications in type 2 diabetes ("Temporary worsening of diabetic retinopathy has been reported with rapid improvement in glucose control. Patients with a history of diabetic retinopathy should be monitored for progression of diabetic retinopathy."); 5.9 pulmonary aspiration during general anaesthesia or deep sedation; 5.10 "Never share ZEPBOUND KwikPen between patients, even if the pen needle is changed." Under drug interactions (7.2) the label says tirzepatide delays gastric emptying and may affect the absorption of oral medicines, and to monitor patients on narrow-therapeutic-index medicines such as warfarin; it may reduce the efficacy of oral hormonal contraceptives. Under pregnancy it says: "Weight loss offers no benefit to a pregnant patient and may cause fetal harm." (Zepbound label). The Mounjaro label has its own text for diabetes.
  • Gastrointestinal events were the most common adverse events in the tirzepatide and cagrilintide trials alike. In REDEFINE 1 they affected 79.6% on CagriSema and 39.9% on placebo (PMID 40544433).
  • Cagrilintide on its own. Beyond the trials above, a 30-person arm of a phase 2 diabetes trial exists (PMID 37364590). A 2026 meta-analysis that pooled the cagrilintide-alone groups of two trials (Lau 2021 and Garvey 2025) reported a mean body-weight difference of 6.08% against placebo (95% confidence interval 4.14 to 8.02), with substantial heterogeneity (I² = 89%, meaning the trials' results differed widely), without meaningful HbA1c improvement, and "modest but statistically significant increases in adverse events" (PMID 42583410). Long-term effects of cagrilintide alone are unknown.
  • Duration. The main treatment periods in the published trials above were up to 72 weeks; the registered head-to-head obesity trial lists up to 84 weeks.

UK regulatory position

This site gives no legal advice or sourcing information and does not sell anything. Rules on unauthorised medicines exist in the Human Medicines Regulations 2012. Whether a particular product is a medicinal product under regulation 2 depends on its specifics, including how it is presented and how it functions. For questions about medicines speak to a GP or pharmacist; problems with a medicine can be reported to the MHRA through the Yellow Card scheme.

The MHRA states: "In the UK, there are several licensed GLP-1 medicines including semaglutide (sold under the brand names Wegovy, Ozempic and Rybelsus), tirzepatide (Mounjaro) and liraglutide (sold under various brand names)." (MHRA, GOV.UK, page updated 5 February 2026)

For cagrilintide, a DailyMed search for "cagrilintide" and for "CagriSema" on 6 November 2026 returned no entries, and an openFDA search for the substance name "cagrilintide" returned no record. See what the MHRA says about advertising prescription-only medicines and the GLP-1 advertising caution for the MHRA material on advertising.

Verdict — research-question matching

These are different drugs with different evidence. Tirzepatide has been tested alone against placebo in large trials, such as SURMOUNT-1 (2,539 adults, 72 weeks). Cagrilintide has been tested alone in a 26-week phase 2 trial (706 adults), as a 2.4 mg arm of a phase 2 diabetes trial (30 adults) and as a 2.4 mg arm in two phase 3 trials (11.8% weight loss in REDEFINE 1), but most of its phase 3 results are for CagriSema, its combination with semaglutide. No published trial compares tirzepatide with cagrilintide or CagriSema (PubMed search, 6 November 2026); trials of CagriSema against tirzepatide are registered and had no results posted on that date.

References

Peer-reviewed sources for the claims above. Where an editor has verified study type, sample size, outcome and limitation, the citation is rendered as a card; otherwise as a plain reference. Links open PubMed or the journal DOI.

  1. Jastreboff AM, Aronne LJ, Ahmad NN, et al.. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022;387(3) :205-216 doi:10.1056/NEJMoa2206038 · PMID: 35658024
  2. Lau DCW, Erichsen L, Francisco AM, et al.. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet. 2021;398(10317) :2160-2172 doi:10.1016/S0140-6736(21)01751-7 · PMID: 34798060
  3. Kruse T, Hansen JL, Dahl K, et al.. Development of Cagrilintide, a Long-Acting Amylin Analogue. Journal of Medicinal Chemistry. 2021;64(15) :11183-11194 doi:10.1021/acs.jmedchem.1c00565 · PMID: 34288673
  4. Garvey WT, Blüher M, Osorto Contreras CK, et al.. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2025;393(7) :635-647 doi:10.1056/NEJMoa2502081 · PMID: 40544433
  5. Davies MJ, Bajaj HS, Broholm C, et al.. Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. New England Journal of Medicine. 2025;393(7) :648-659 doi:10.1056/NEJMoa2502082 · PMID: 40544432
  6. Enebo LB, Berthelsen KK, Kankam M, et al.. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial. Lancet. 2021;397(10286) :1736-1748 doi:10.1016/S0140-6736(21)00845-X · PMID: 33894838
  7. Buse JB, Bajaj HS, Dalskov SM, et al.. Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study. Lancet Diabetes & Endocrinology. 2026;14(8) :662-677 doi:10.1016/S2213-8587(26)00125-7 · PMID: 42251859
  8. Aroda VR, Buzzetti R, Dalskov SM, et al.. Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study. Lancet Diabetes & Endocrinology. 2026;14(8) :649-661 doi:10.1016/S2213-8587(26)00126-9 · PMID: 42251860
  9. Frias JP, Deenadayalan S, Erichsen L, et al.. Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. Lancet. 2023;402(10403) :720-730 doi:10.1016/S0140-6736(23)01163-7 · PMID: 37364590
  10. Yaseen M, Ameer A, Ali Z, et al.. Amylin-based obesity therapy: a meta-analysis of Cagrilintide and CagriSema versus placebo. Annals of Medicine and Surgery. 2026;88(8) :5317-5326 doi:10.1097/MS9.0000000000005353 · PMID: 42583410
  11. Verma S, Böttcher M, Brown P, et al.. CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1. Hypertension. 2026;83(2) :e26055 doi:10.1161/HYPERTENSIONAHA.125.26055 · PMID: 41328546
Published: 2026-07-25Last updated: 2026-11-06
  • Correction (2026-11-06): Corrected 6 November 2026 after a dose and citation audit: the claim that cagrilintide was never tested alone was wrong and was corrected; tirzepatide label warnings and registered head-to-head trials were added; unsourced mechanism and half-life statements were removed.

If you spot an error or have new evidence to suggest, please use our corrections policy.

Continue reading